Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pearl Therapeutics

- PMLiVE

LEO Pharma picks up AZ skin disease drugs in $1bn deal

Gains rights to eczema and psoriasis treatments

- PMLiVE

US cuts at Boehringer hit sales force hardest

And Arena Pharmaceuticals plans US and Swiss 'reductions'

- PMLiVE

Just:: Health Communications becomes HAVAS Just::

Healthcare agency changes name one year after its acquisition by HAVAS Health

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Boehringer Ingelheim launches ‘gamified’ COPD initiative

Programme aims to encourage and reward disease management

Sanofi reception

Sanofi moves to replace Medivation board

Ramps up efforts to seize control of its US biopharma takeover target

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

- PMLiVE

AstraZeneca sells rights to seven anaesthetics in $770m deal

Ten-year agreement with Aspen continues the streamlining of its operations

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links